Phosphodiesterase 5A as a target in cardiac disease

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 5, 2005, Pages 1097-1100

  Doggrell, Sheila A ^a  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Cardiac hypertrophy; Doxorubicin induced cardiomyopathy; Phosphodiesterase 5A (PDE5A); Pressure overload; Sildenafil

Indexed keywords

CALCINEURIN; CASPASE 3; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DOXORUBICIN; EMD 360527; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PROTEIN KINASE B; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART PROTECTION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMEGALY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DOXORUBICIN; MICE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; SULFONES;

EID: 27144520061     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.5.1097     Document Type: Article

References (6)

1. KISHIMOTO I, ROSSI K, GARBERS DL: A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. (2001) 98:2703-2706.
2. YANAKA N, KOTERA J, OHTSUKA A et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur. J. Biochem. (1998) 255:391-399.
3. TAKIMOTO E, CHAMPION HC, LI M et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. (2005) 11:214-222.
4. ATP channels in rabbits. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:H1263-H1269.
5. FISHER PW, SALLOUM F, DAS A, HYDER H, KUKREJA R: Phosphodisesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation (2005) 111:1601-1610.
6. HASSAN MAH, KETAT AF: Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol. (2005) 5(1)10.